Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Managing active and healthy aging with use of caring service robots

MARIO

MARIO addresses the difficult challenges of loneliness, isolation and dementia in older persons through innovative and multi-faceted inventions delivered by service robots. The effects of these conditions are severe and life-limiting. They burden individuals and societal support systems. Human intervention is costly but the severity can be...

Funding Programme
Start Date
End Date
Total Funding
€ 3 994 857
European Countries Involved

Memory loss in Alzheimer disease: underlying mechanisms and therapeutic targets

MEMOSAD

MEMOSAD aims at defining the molecular mechanisms of Abeta- and Tau-induced synaptotoxicity and at developing disease-modifying therapeutics for the prevention of memory loss in Alzheimer disease (AD). Insoluble aggregates of the two proteins provide the pathological hallmarks of this incurable brain disorder. Early stage AD is characterized by a...

Funding Programme
Start Date
End Date
Total Funding
€ 4 023 080
European Countries Involved

Memory research: Ground-breaking, Applied, and Technological Exchanges

M-GATE

In M-GATE, ESRs will combine state-of-the art experimental neurophysiology, innovative technologies, and advanced theoretical approaches to unveil memory mechanisms, from single neurons to brain networks, to cognition and behaviour, addressing the healthy and diseased brain. Through research and training from top-class scientists and close...

Funding Programme
Start Date
End Date
Total Funding
€ 3 961 160
European Countries Involved

Microbiome-Microglia interaction in Alzheimer's disease

MiMi-AD

Alzheimer’s disease (AD) affects over 55 million people worldwide, with no effective treatments currently available. Understanding early-stage mechanisms of the disease is critical to developing new therapeutic approaches. Microglial cells, key regulators of amyloid-beta (Aβ) clearance and neuroinflammation, are implicated in the progression of AD...

Funding Programme
Start Date
End Date
Total Funding
€ 226 420
European Countries Involved

MiCrovasculaR rarefaction in vascUlar Cognitive Impairement and heArt faiLure

CRUCIAL

Vascular dementia and heart failure represent major health burden to morbidity, mortality and quality of life. Comorbidities (hypertension, aging, diabetes, etc.) affect all organs, but the brain and heart are especially sensitive to these chronic stresses resulting in cognitive impairment (a mental disorder) and heart failure (a non-mental...

Funding Programme
Start Date
End Date
Total Funding
€ 6 000 000
European Countries Involved

Mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics

MITOTARGET

Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where...

Funding Programme
Start Date
End Date
Total Funding
€ 10 332 038
European Countries Involved

Molecular physiology of nerve terminal bioenergetics

SynaptoEnergy

Synaptic transmission is an extremely energetically-demanding process that consumes 75% of the energy required for brain function. However, it remains poorly understood how synapses guarantee the necessary ATP levels required for neurotransmission. While our understanding of the metabolic pathways for ATP production is vastly detailed, very little...

Funding Programme
Start Date
End Date
Total Funding
€ 1 494 605
European Countries Involved

Molecular Structure and Engineering of Synaptic Organizer Proteins in Health and Disease

SynLink

Synapses are the specialized cellular junctions that form the basic units of communication between neuronal cells. Given the variety of network-dependent functions that synapses need to support, a fundamental question is how their properties are specified at the molecular level. Membrane-anchored and soluble “synaptic organizer proteins” form...

Funding Programme
Start Date
End Date
Total Funding
€ 1 499 903
European Countries Involved

Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis

MIRIADE

Dementia is currently diagnosed largely based on cognitive decline, while pathology starts years before symptom onset. To make progress in the development of effective drugs for dementia, there is an urgent need for biomarkers to enable precision health: for early and specific diagnosis and objective monitoring of disease progression. With its...

Funding Programme
Start Date
End Date
Total Funding
€ 4 034 565

Multimodal preventive trials for Alzheimer’s Disease: towards multinational strategies

MIND-AD

The anticipated pandemic increase in the number of Alzheimer disease (AD) and dementia cases carries serious implications for society. The goal of the MIND-AD project is to identify effective prevention strategies for AD/dementia tailored to different at-risk groups. The project is based on experiences and data from five ongoing European...

Funding Programme
Start Date
End Date
Total Funding
€ 0
European Countries Involved

NAD+ International Scientist-training

NADIS

Nicotinamide adenine dinucleotide (NAD+) is a central redox cofactor and the limiting substrate of key metabolic enzymes. The constellation of cellular functions in which NAD+ is involved makes its availability critical for cell survival, and its depletion is a leading factor in a number of diseases in humans, ranging from rare inherited defects to...

Funding Programme
Start Date
End Date
Total Funding
€ 2 530 832
European Countries Involved

NANOPARTICLES FOR THERAPY AND DIAGNOSIS OF ALZHEIMER DISEASE

NAD

The search for effective therapies and early detection strategies for Alzheimer’s Disease (AD), the major cause of dementia in Europe, is imperative. It is known that β-amyloid (Aβ) peptide plays a central role in neurodegeneration. In AD brain, Aβ is released in a soluble form that progressively becomes insoluble forming aggregates; extracellular...

Funding Programme
Start Date
End Date
Total Funding
€ 14 365 090
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).